^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    guadecitabine (SGI-110)

    i
    Other names: SGI-110, S-110, SGI110, SGI 110, S110
    Associations

    News

    Trials
    Company:
    Otsuka
    Drug class:
    DNMT inhibitor
    Related drugs:
    Associations

    News

    Trials
    3ms
    Epigenetic Modulation and Bone Metastasis: Evolving Therapeutic Strategies. (PubMed, Pharmaceuticals (Basel))
    DNA methyltransferase inhibitors (e.g., decitabine, guadecitabine) have shown promise in attenuating osteoclast differentiation, while histone deacetylase inhibitors display context-dependent effects on tumor progression and bone remodeling...Together, these advances position epigenetic modulation as a promising axis in precision oncology aimed at interrupting the pathological crosstalk between tumor cells and the bone microenvironment. This review synthesizes current mechanistic understanding, evaluates the therapeutic landscape, and outlines the translational challenges ahead in leveraging epigenetic science to prevent and treat bone metastases.
    Review • Journal • IO biomarker
    |
    SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • MIR34A (MicroRNA 34a-5p) • RASSF1 (Ras Association Domain Family Member 1) • NORAD (Non-Coding RNA Activated By DNA Damage)
    |
    guadecitabine (SGI-110)
    4ms
    Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer. (clinicaltrials.gov)
    P1, N=28, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jul 2025 --> Jul 2026 | Trial primary completion date: Jul 2025 --> Jul 2026
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • mocetinostat (MGCD0103) • guadecitabine (SGI-110)
    4ms
    NCI-2016-01233: Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed (clinicaltrials.gov)
    P1/2, N=33, Active, not recruiting, University of Southern California | Trial completion date: Nov 2025 --> Dec 2026 | Trial primary completion date: Nov 2024 --> Dec 2025
    Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    Tecentriq (atezolizumab) • guadecitabine (SGI-110)
    9ms
    Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P1/2, N=12, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | N=75 --> 12
    Trial completion • Enrollment change • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CTAG1B (Cancer/testis antigen 1B)
    |
    Tecentriq (atezolizumab) • Hiltonol (poly-ICLC) • guadecitabine (SGI-110) • rasdegafusp alfa (CDX-1401)
    9ms
    Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer (clinicaltrials.gov)
    P1, N=55, Active, not recruiting, University of Southern California | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Mar 2021 --> Apr 2024
    Trial completion date • Trial primary completion date
    |
    Imfinzi (durvalumab) • guadecitabine (SGI-110)
    9ms
    The Role of the DNA Methyltransferase Family and the Therapeutic Potential of DNMT Inhibitors in Tumor Treatment. (PubMed, Curr Oncol)
    Improving the treatment schedules, increasing isoform specificity, reducing toxicity, and utilizing genome-wide analyses of CRISPR-based editing to create personalized epigenetic therapies tailored to individual patient needs are promising strategies for enhancing therapeutic outcomes. This review discusses the interaction between DNMT regulators and DNMT1, its binding partners, the connection between DNA methylation and tumors, how these processes contribute to tumor development, and DNMT inhibitors' advancements and pharmacological properties.
    Review • Journal • IO biomarker
    |
    DNMT1 (DNA methyltransferase 1)
    |
    guadecitabine (SGI-110)
    12ms
    ETCTN: Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma (clinicaltrials.gov)
    P2, N=32, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2025 --> Jun 2025 | Trial primary completion date: Jan 2025 --> Jun 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    Inqovi (decitabine/cedazuridine) • Beleodaq (belinostat) • guadecitabine (SGI-110)
    1year
    NCI-2016-00343: Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant (clinicaltrials.gov)
    P2, N=55, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed
    Trial completion
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
    |
    guadecitabine (SGI-110)
    over1year
    Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer. (clinicaltrials.gov)
    P1, N=28, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • mocetinostat (MGCD0103) • guadecitabine (SGI-110)
    over1year
    NCI-2014-02377: Guadecitabine in Treating Patients With Higher-Risk Myelodysplastic Syndromes (clinicaltrials.gov)
    P2, N=100, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | N=71 --> 100 | Trial completion date: Nov 2024 --> Jul 2024 | Trial primary completion date: Nov 2024 --> Jul 2024
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    guadecitabine (SGI-110)
    over1year
    Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer (clinicaltrials.gov)
    P1, N=55, Active, not recruiting, University of Southern California | Trial completion date: Jun 2024 --> Dec 2024
    Trial completion date • Metastases
    |
    Imfinzi (durvalumab) • guadecitabine (SGI-110)
    over1year
    ETCTN: Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma (clinicaltrials.gov)
    P2, N=32, Active, not recruiting, National Cancer Institute (NCI) | Suspended --> Active, not recruiting
    Enrollment closed • Metastases
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    Inqovi (decitabine/cedazuridine) • Beleodaq (belinostat) • guadecitabine (SGI-110)